Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest CD4 Stories

2013-01-17 13:30:25

Earlier therapy enhances restoration of CD4+ T-cell counts Patients who are started on antiretroviral therapy for HIV-1 infection within four months of estimated infection date – and who have higher counts of CD4+ T-cells at the initiation of therapy – demonstrate a stronger recovery of CD4+ T-cell counts than patients in whom therapy is started later, a new study shows. The report, to be published Thursday in The New England Journal of Medicine, is co-authored by physicians...

2012-12-19 11:30:11

Scientists from the AIDS Research Institute IrsiCaixa have identified how HIV, the virus that causes AIDS, enters the cells of the immune system enabling it to be dispersed throughout an organism. The new study is published December 18 in the open access journal PLOS Biology. One of the reasons why we do not yet have a cure for HIV infection is that the virus infects cells of the immune system that would normally fight such an infection. The main targets of HIV are white blood cells named...

2012-09-12 00:57:17

Novel method could help advance the fight against persistent 'HIV latency' Scientists at the Gladstone Institutes have gotten us one step closer to understanding and overcoming one of the least-understood mechanisms of HIV infection–by devising a method to precisely track the life cycle of individual cells infected with HIV, the virus that causes AIDS. In a paper being published online today in Lab on a Chip, the laboratory of Gladstone Investigator Leor Weinberger, PhD, announced...

2012-09-10 06:30:48

RICHMOND, Calif., Sept. 10, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced that data from its Phase 1 clinical programs to develop SB-728-T, a novel therapeutic approach designed to generate a "functional cure" for HIV/AIDS, were presented at the 52(nd )Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). The meeting is being held in San Francisco from September 9-12, 2012. "The immunologic data presented at ICAAC have predictive...

2012-08-01 10:39:48

In a first-of-its-kind health campaign in Uganda, researchers from the University of North Carolina at Chapel Hill show that adults with HIV who had less severe infections could work more hours per week, and their children were more likely to be enrolled in school. The finding, led by Harsha Thirumurthy, Ph.D., a health economist at UNC´s Gillings School of Global Public Health, not only could mean greater earning potential for people with HIV, but also a better economic outlook for...

2012-06-20 02:26:12

MELBOURNE, Australia, June 20, 2012 /PRNewswire/ -- For the first time, HIV patients in developing countries will have access to an affordable diagnostic test to determine if they should start life-saving antiretroviral drugs. The Burnet Institute in Melbourne has announced a licensing agreement with Omega Diagnostics Group PLC, a global diagnostics organisation, to commercialise the point-of-care CD4 test for use worldwide, including aid agencies delivering frontline health services....

2012-06-05 06:28:19

WORCESTER, Mass. and TORONTO, June 5, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT.OB) announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (http://chicago2012.asco.org) on June 2, 2012 in Chicago, IL. The abstract entitled: 'An assessment of...

2012-04-18 19:59:54

In wealthy countries, antiretroviral therapy (ART) has transformed AIDS into an often-manageable chronic condition, as patients can receive both the therapeutics and the constant monitoring that ensures the therapies remain effective. Developing nations, however, frequently need to balance expansion of treatment access versus the economic resources to sustain the routine blood testing that ART requires. At a time when global funding commitments for AIDS therapy programs are being cut, there...

2012-03-27 01:01:41

The hallmark loss of helper CD4+ T cells during human immunodeficiency virus (HIV) infection may be a red herring for therapeutics, according to a study published on March 26th in the Journal of Experimental Medicine. HIV preferentially infects CD4+ T cells, immune cells required to generate protective antibodies. In many people, this leads to a progressive drop in CD4+ T cell numbers–and the more the numbers fall, the faster AIDS develops. HIV-induced cell loss includes both 'naive'...